Development of primary malignant melanoma during treatment with a TNF-α antagonist for severe Crohn’s disease: a case report and review of the hypothetical association between TNF-α blockers and cancer

References

• Katoulis AC Kanelleas A Zambacos G Panayiotides I Stavrianeas NG Development of two primary malignant melanomas after treatment with adalimumab: a case report and review of the possible link between biological therapy with TNF-alpha antagonists and melanocytic proliferation Dermatology 2010 221 1 9 12 20484878
   PubMed Web of Science ®Google Scholar
• Fulchiero GJJr Salvaggio H Drabick JJ Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies J Am Acad Dermatol 2007 56 Suppl 5 S65 S67 17434043
   PubMed Web of Science ®Google Scholar
• Patel RV Clark LN Lebwohl M Weinberg JM Treatments for psoriasis and the risk of malignancy J Am Acad Dermatol 2009 60 6 1001 1017 19344980
   PubMed Web of Science ®Google Scholar
• Krueger JG Bowcock A Psoriasis pathophysiology: current concepts of pathogenesis Ann Rheum Dis 2005 64 Suppl 2 ii30 ii36 15708932
   PubMedGoogle Scholar
• Mahmoud F Abdul H al Saleh Q Elevated B-lymphocyte levels in lesional tissue of non-arthritic psoriasis J Dermatol 1999 26 7 428 433 10458082
   PubMedGoogle Scholar
• Müller KM Röcken M Joel D Bonnefoy JY Saurat JH Hauser C Mononuclear cell-bound CD23 is elevated in both atopic dermatitis and psoriasis J Dermatol Sci 1991 2 2 125 133 1829628
   PubMedGoogle Scholar
• Naldi L Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporine, and biologics: facts and controversies Clin Dermatol 2010 28 1 88 92 20082957
   PubMed Web of Science ®Google Scholar
• Mease PJ Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis Expert Opin Biol Ther 2005 5 11 1491 1504 16255652
   PubMed Web of Science ®Google Scholar
• Diak P Siegel J La Grenade L Choi L Lemery S McMahon A Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration Arthritis Rheum 2010 62 8 2517 2524 20506368
   PubMed Web of Science ®Google Scholar
• Ehlers S Hölscher C Scheu S The lymphotoxin beta receptor is critically involved in controlling infections with the intracellular pathogens Mycobacterium tuberculosis and Listeria monocytogenes J Immunol 2003 170 10 5210 5218 12734369
   PubMed Web of Science ®Google Scholar
• Wallis RS Broder MS Wong JY Hanson ME Beehouwer DO Granulomatous infectious diseases associated with tumor necrosis factor antagonists Clin Infect Dis 2004 38 9 1261 1265 15127338
   PubMed Web of Science ®Google Scholar
• Bongartz T Sutton AJ Sweeting MJ Buchan I Matteson EL Montori V Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 2006 295 19 2275 2285 16705109
   PubMed Web of Science ®Google Scholar
• Stone JH Holbrook JT Marriott MA Wegener’s Granulomatosis Etanercept Trial Research Group Solid malignancies among patients in the Wegener’s Granulomatosis Etanercept Trial Arthritis Rheum 2006 54 5 1608 1618 16646004
   PubMed Web of Science ®Google Scholar
• Brown SL Greene MH Gershon SK Edwards ET Braun MM Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration Arthritis Rheum 2002 46 12 3151 3158 12483718
   PubMed Web of Science ®Google Scholar
• Askling J Fored CM Baecklund E Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumor necrosis factor antagonists Ann Rheum Dis 2005 64 10 1414 1420 15843454
   PubMed Web of Science ®Google Scholar
• Chakravarty EF Michaud K Wolfe F Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors J Rheumatol 2005 32 11 2130 2135 16265690
   PubMed Web of Science ®Google Scholar
• Fryrear RS2nd Wiggins AK Sangueza O Yosipovitch G Rapid onset of cutaneous squamous cell carcinoma of the penis in a patient with psoriasis on etanercept therapy J Am Acad Dermatol 2004 51 6 1026 15583608
   PubMed Web of Science ®Google Scholar
• Euvrard S Kanitakis J Claudy A Skin cancers after organ transplantation N Engl J Med 2003 348 17 1681 1691 12711744
   PubMed Web of Science ®Google Scholar
• Smith KJ Skelton HG Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy J Am Acad Dermatol 2001 45 6 953 956 11712048
   PubMed Web of Science ®Google Scholar
• Esser AC Abril A Fayne S Doyle JA Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab J Am Acad Dermatol 2004 50 Suppl 5 S75 S77 15097933
   PubMed Web of Science ®Google Scholar
• Askling J Fored CM Brandt L Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumor necrosis factor antagonists Ann Rheum Dis 2005 64 10 1421 1426 15829572
   PubMed Web of Science ®Google Scholar
• Ly L Czarnecki D The rapid onset of multiple squamous cell carcinomas during etanercept treatment for psoriasis Br J Dermatol 2007 157 5 1076 1078 17854370
   PubMed Web of Science ®Google Scholar
• Nair B Raval G Mehta P TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature Am J Hematol 2007 82 11 1022 1024 17654504
   PubMed Web of Science ®Google Scholar
• Hurley MY George MN Leonardi CL Frater JL A transient benign lymph node-based proliferation of T-cells stimulating non-Hodgkin lymphoma in a patient with psoriasis treated with tumor necrosis factor alpha and CD11a antagonists Diagn Pathol 2008 3 13 18 18366773
   PubMed Web of Science ®Google Scholar
• Tyring S Gordon KB Poulin Y Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis Arch Dermatol 2007 143 6 719 726 17576937
   PubMed Web of Science ®Google Scholar
• Girard C Guillot B Bessis D Gastric MALT lymphoma in a patient receiving infliximab for psoriasis Br J Dermatol 2008 159 2 497 498 18547313
   PubMed Web of Science ®Google Scholar
• Kouklakis G Efremidou EI Zezos P Adalimumab: an effective and promising treatment for patients with fistulizing Crohn’s disease: a case series J Med Case Rep 2011 5 109 21418588
   PubMedGoogle Scholar
• Penn I Malignant melanoma in organ allograft recipients Transplantation 1996 61 2 274 278 8600636
   PubMed Web of Science ®Google Scholar
• Gordon KB Langley RG Leonardi C Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study J Am Acad Dermatol 2006 55 4 598 606 17010738
   PubMed Web of Science ®Google Scholar
• Kowalzick L Eickenscheidt L Komar M Schaarschmidt E Long term treatment of psoriasis with TNF-alpha antagonists: occurrence of malignant melanoma Hautarzt 2009 60 8 655 657 German [with English abstract] 19280165
   PubMed Web of Science ®Google Scholar
• Khan I Rahman L McKenna DB Primary cutaneous melanoma: a complication of infliximab treatment? Clin Exp Dermatol 2009 34 4 524 526 19196307
   PubMed Web of Science ®Google Scholar
• Seminerio JL Loftus EVJr Colombel JF Thapa P Sandborn WJ Infliximab for Crohn’s disease: the first 500 patients followed up through 2009 Dig Dis Sci Epub 9 29 2012
   Google Scholar
• Burmester GR Panaccione R Gordon KB McIlraith MJ Lacerda AP Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease Ann Rheum Dis Epub 7 6 2012
   Google Scholar